Selinexor with pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma

Selinexor with pomalidomide and dexamethasone is in development for the treatment of patients with relapsed or refractory multiple myeloma (MM) who have received 1 to 4 prior treatments. MM is a type of blood cancer that develops within bones. The cancerous cells can damage the bones and affect their ability to create healthy blood cells. Relapsed cancer is where it has returned after a period of improvement. Refractory cancer is where it doesn’t respond well to treatments.